Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

804 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumor Therapy. Rivera F, et al. Among authors: anton a. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1430-6. doi: 10.1016/j.ijrobp.2008.12.087. Epub 2009 Jun 18. Int J Radiat Oncol Biol Phys. 2009. PMID: 19540072 Clinical Trial.
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, Laquente B, Rodríguez E, Carrato A, Escudero P, Massutí B, Alonso-Orduña V, Cardenal A, Sáenz A, Giralt J, Yuste AL, Antón A, Aranda E; Spanish Cooperative Group for Digestive Tumour Therapy (TTD). Rivera F, et al. Among authors: anton a. Cancer Chemother Pharmacol. 2011 Jan;67(1):75-82. doi: 10.1007/s00280-010-1285-1. Epub 2010 Mar 3. Cancer Chemother Pharmacol. 2011. PMID: 20198372 Clinical Trial.
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Abad A, Massuti B, Antón A, Vega ME, Yuste AL, Marcuello E, Manzano JL, Alonso V, Carrato A, Martinez-Villacampa M, Tabernero J, Aranda E, Rivera F, Díaz-Rubio E; Spanish Cooperative Group for Digestive Tumor Therapy. Abad A, et al. Among authors: anton a. Acta Oncol. 2008;47(2):286-92. doi: 10.1080/02841860701630259. Acta Oncol. 2008. PMID: 17957505 Clinical Trial.
A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Alsina M, et al. Among authors: anton a. Target Oncol. 2018 Feb;13(1):69-78. doi: 10.1007/s11523-017-0536-z. Target Oncol. 2018. PMID: 29128908 Clinical Trial.
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer.
Abad A, Carrato A, Navarro M, Sastre J, Cervantes A, Antón A, Martinez-Villacampa M, Marcuello E, Massutí B, Aranda E, Manzano JL, Guallar JL, Diaz-Rubio E. Abad A, et al. Among authors: anton a. Clin Colorectal Cancer. 2005 Mar;4(6):384-9. doi: 10.3816/ccc.2005.n.010. Clin Colorectal Cancer. 2005. PMID: 15807931 Clinical Trial.
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. Díaz-Rubio E, et al. Among authors: anton a. Oncologist. 2012;17(1):15-25. doi: 10.1634/theoncologist.2011-0249. Epub 2012 Jan 10. Oncologist. 2012. PMID: 22234633 Free PMC article. Clinical Trial.
Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, Isla D, Vega ME, Martí JL, Lobo F, Pastor P, Valentí V, Belón J, Sánchez MA, Chaib C, Pallarés C, Antón A, Cervantes A, Paz-Ares L, Cortés-Funes H. Hitt R, et al. Among authors: anton a. J Clin Oncol. 2005 Dec 1;23(34):8636-45. doi: 10.1200/JCO.2004.00.1990. Epub 2005 Nov 7. J Clin Oncol. 2005. PMID: 16275937 Clinical Trial.
Correction to: A Phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients.
Alsina M, Rivera F, Ramos FJ, Galán M, López R, García-Alfonso P, Alés-Martinez JE, Queralt B, Antón A, Carrato A, Grávalos C, Méndez-Vidal MJ, López C, de Mena IR, Tabernero J, Giralt J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD) and Grupo de Investigación Clínica en Oncología Radioterápica (GICOR). Alsina M, et al. Among authors: anton a. Target Oncol. 2018 Feb;13(1):79. doi: 10.1007/s11523-017-0544-z. Target Oncol. 2018. PMID: 29243205 Free article.
804 results